Journal of Gastroenterology

, Volume 31, Issue 5, pp 702–709 | Cite as

Effects of high-dose intraperitoneal aprotinin treatment on complement activation and acute phase response in acute severe pancreatitis

  • Rikard Berling
  • Kjell Ohlsson
Liver, Pancreas, and Biliary Tract

Abstract

Forty-eight patients with severe acute pancreatitis were treated with intraperitoneal lavage in a double-blind randomized multi-center trial. One group (aprotinin group,n=22) was also treated intraperitoneally with high doses of the protease inhibitor aprotinin. In the group not treated with aprotinin (control group), 6 patients were operated on because of pancreatic necrosis, compared with none in the treated group. Complement activation and the acute phase response were studied with measurements of anaphylatoxin C3a, C1 inhibitor (C1 Inh), interleukin 6 (IL-6), and C-reactive protein (CRP). The control group had higher plasma levels of C3a and lower levels of C1 Inh compared with the aprotinin group. The differences were statistically significant for C3a but not for C1 Inh. Both groups had high plasma levels of IL-6 and CRP. There were no differences between the groups in CRP levels, but the control group had higher IL-6 levels (not statistically significant) than the aprotinin group. This was caused by very high levels in the 6 patients operated on because of pancreatic necrosis, indicating that IL-6 could be a good plasma marker of pancreatic necrosis. The results also show that massive antiprotease treatment reduces complement activation, as illustrated by the lower C3a levels in the aprotinin group. The lower C1 Inh levels in the control group could have been caused by an increased consumption of the inhibitor.

Key words

acute pancreatitis acute phase response aprotinin complement activation IL-6 CRP pancreatic necrosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chiari H. Über die Selbstverdaung des menshlichen Pankreas. Z Helik 1896;17:69–96.Google Scholar
  2. 2.
    Ohlsson K. Experimental pancreatitis in the dog. Appearance of complexes between proteases and trypsin inhibitors in ascitic fluid, lymph and plasma. Scand J Gastroenterol 1971;6:642–652.Google Scholar
  3. 3.
    Geokas MC, Rinderknecht H. Free proteolytic enzymes in pancreatic juice of patients with acute pancreatitis. Am J Dig Dis 1974;19:591–598.CrossRefPubMedGoogle Scholar
  4. 4.
    Ohlsson K, Eddeland A. Release of proteolytic enzymes in bile-induced pancreatitis in dogs. Gastroenterology 1975;69:668–675.PubMedGoogle Scholar
  5. 5.
    Rao KN, Tuma J, Lombardi B. Acute hemorrhagic pancreatic necrosis in mice: Intraparenchymal activation of zymogens and other enzyme changes in pancreas and serum. Gastroenterology 1976;70:720–726.PubMedGoogle Scholar
  6. 6.
    Borgström A, Ohlsson K. Immunoreactive trypsin in serum and peritoneal fluid in acute pancreatitis. Hoppe-Seyler's Z Physiol Chem 1978;359:677–681.PubMedGoogle Scholar
  7. 7.
    Yamaguchi H, Kimura T, Mimura K, Nawata H. Activation of proteases in cerulein-induced pancreatitis. Pancreas 1989;4:565–571.PubMedGoogle Scholar
  8. 8.
    Heath DI, Cruickshank A, Gudgeon AM, et al. The relationship between pancreatic enzyme release and activation and the acutephase protein response in patients with acute pancreatitis. Pancreas 1995;10:347–353.CrossRefPubMedGoogle Scholar
  9. 9.
    Hirano T, Manabe T, Tobe T. Protection by gabexate mesilate (FOY) of the exocrine pancreas in rats with acute pancreatitis induced by a supramaximal dose of caerulein. J Gastroenterol Hepatol 1991;6:260–264.PubMedGoogle Scholar
  10. 10.
    Fric P, Slaby J, Kasafirek E, et al. Effective peritoneal therapy of acute pancreatitis in the rat with glutaryl-trialanin-ethylamide: A novel inhibitor of pancreatic elastase. Gut 1992;33:701–706.PubMedGoogle Scholar
  11. 11.
    Trapnell JE, Rigby CC, Talbot CH, Duncan EHL. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg 1974;61:177–182.PubMedGoogle Scholar
  12. 12.
    Imrie CW, Benjamin IS, Ferguson JC, et al. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg 1978;65:337–341.PubMedGoogle Scholar
  13. 13.
    Medical Research Council Multicentre Trial. Morbidity of acute pancreatitis: The effect of aprotinin and glucagon. Gut 1980;21:334–339.Google Scholar
  14. 14.
    Pederzoli P, Bassi C, Cavallini G, et al. The Italian multicenter trial on gabexate mesilate versus aprotinin in human acute pancreatitis (abstract from European Pancreatic Club meeting September 16–18, 1991). Digestion 1991;49(1):43.Google Scholar
  15. 15.
    Larvin M, Wilson C, Heath D, et al. Intraperitoneal aprotinin therapy and the clinical course of acute pancreatitis. Br J Surg 1992;79:456–457.Google Scholar
  16. 16.
    Berling R, Genell S, Ohlsson K. High-dose intraperitoneal aprotinin treatment of acute severe pancreatitis: A double-blind randomized multi-center trial. J Gastroenterol 1994;29:479–485.PubMedGoogle Scholar
  17. 17.
    Ranson JHC, Rifkind KM, Roses DF, et al. Prognostic signs and the role of operation management in acute pancreatitis. Surg Gynecol Obstet 1974;139:69–81.PubMedGoogle Scholar
  18. 18.
    Wilson C, Heath DI, Imrie CW. Prediction of outcome in acute pancreatitis: A comparative study of APACHE II, clinical assessment and multiple factor scoring systems. Br J Surg 1990;77:1260–1264.PubMedGoogle Scholar
  19. 19.
    Tran DD, Cuesta MA. Evaluation of severity in patients with acute pancreatitis. Am J Gastroenterol 1992;87:604–608.PubMedGoogle Scholar
  20. 20.
    Silverstein W, Isikoff MB, Hill MC, Barkin J. Diagnostic imaging of acute pancreatitis. Am J Roentgenol 1981;137:497–502.Google Scholar
  21. 21.
    Balthazar EJ, Robinson DL, Megibow AJ, Ranson JHC. Acute pancreatitis: Value of CT in establishing prognosis. Radiology 1990;174:331–336.PubMedGoogle Scholar
  22. 22.
    Warshaw A, Lee K. Serum ribonuclease elevations and pancreatic necrosis in acute pancreatitis. Surgery 1979;86:227–232.PubMedGoogle Scholar
  23. 23.
    Schröder T, Kivilaakso E, Kinnunen PKJ, Lempinen M. Serum phospholipase A2 in human acute pancreatitis. Scand J Gastroenterol 1980;15:633–636.PubMedGoogle Scholar
  24. 24.
    McMahon MJ, Bowen M, Mayer AD, Cooper EH. Relationship of α-2-macroglobulin and other antiproteases to the clinical features of acute pancreatitis. Am J Surg 1984;147:164–169.CrossRefPubMedGoogle Scholar
  25. 25.
    Lasson Å, Ohlsson K. Changes in the kallikrein kinin system during acute pancreatitis in man. Thromb Res 1984;35:27–41.CrossRefPubMedGoogle Scholar
  26. 26.
    Lasson Å, Balldin G, Ohlsson K. Leukocyte elastase 708-1 inhibitor complexes may diagnose pancreatic abscesses early. Scand J Gastroenterol 1986;21:221–224.PubMedGoogle Scholar
  27. 27.
    Puolakkainen P, Valtonen V, Paananen A, Schröder T. C-reactive protein (CRP) and serum phospholipase A2 in the assessment of the severity of acute pancreatitis. Gut 1987;28:764–771.PubMedGoogle Scholar
  28. 28.
    Berling R, Lasson Å, Axelsson L, et al. Plasma CRP levels in the prediction of complications during acute pancreatitis. Surg Res Comm 1990;8:241–249.Google Scholar
  29. 29.
    Windsor JA, Fearon KCH, Ross JA, et al. Role of serum endotoxin and antiendotoxin core antibody levels in predicting the development of multiple organ failure in acute pancreatitis Br J Surg 1993;80:1042–1046.PubMedGoogle Scholar
  30. 30.
    Roxvall L, Bengtsson A, Heideman M. Anaphylatoxin generation in acute pancreatitis. J Surg Res 1989;47:138–143.CrossRefPubMedGoogle Scholar
  31. 31.
    Schapira M, de Agostini A, Schifferli JA, Colman RW. Biochemistry and pathophysiology of human C1 inhibitor: Current issues. Complement 1985;2:111–126.PubMedGoogle Scholar
  32. 32.
    Prograis LJ, Brickman CM, Frank MM. C1 inhibitor (C1-INH). J Med 1985;16:303–350.PubMedGoogle Scholar
  33. 33.
    Mayer AD, McMahon MJ, Bowen M, Cooper EH. C-reactive protein: An aid to assessment and monitoring of acute pancreatitis. J Clin Pathol 1984;37:207–211.PubMedGoogle Scholar
  34. 34.
    Büchler M, Malfertheimer P, Schoetensack C, et al. Sensitivity of antiproteases, complement factors and C-reactive protein in detecting pancreatic necrosis. Results of a prospective clinical study. Int J Pancreatol 1986;1:227–235.PubMedGoogle Scholar
  35. 35.
    Wilson C, Heads A, Shenkin A, Imrie CW. C-reactive protein, antiproteases and complement factors as objective markers of severity in acute pancreatitis. Br J Surg 1987;76:177–181.Google Scholar
  36. 36.
    Castell JV, Gómez-Lechón MJ, David M, et al. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 1988; 232:347–350.CrossRefPubMedGoogle Scholar
  37. 37.
    Morrone G, Ciliberto G, Oliviero S, et al. Recombinant interleukin 6 regulates the transcriptional activation of a set of human acute phase genes. J Biol Chem 1988;263:12554–12558.PubMedGoogle Scholar
  38. 38.
    Leser H-G, Gross V, Scheibenbogen C, et al. Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. Gastroenterology 1991;101:782–785.PubMedGoogle Scholar
  39. 39.
    Viedma JA, Pérez-Mateo M, Domínguez JE, Carballo F. Role of interleukin-6 in acute pancreatitis. Comparison with C-reactive protein and phospholipase A. Gut 1992;33:1264–1267.PubMedGoogle Scholar
  40. 40.
    Heath DI, Cruickshank A, Gudgeon M, et al. Role of interleukin-6 in mediating the acute phase response and potential as an early means of severity assessment in acute pancreatitis. Gut 1993;34:41–45.PubMedGoogle Scholar
  41. 41.
    Laurell C-B. Electroimmunoassay. Scand J Clin Lab Invest 1972;29(Suppl 124):21–37.Google Scholar
  42. 42.
    Gallimore MJ, Friberg P. Simple chromogenic peptide substrat assays for determing prekallikrein, kinin and kallikrein “like” activity in human plasma. Thromb Res 1982;25:293–298.PubMedGoogle Scholar
  43. 43.
    Boyden A, Button E, Germerog D. Precipitin testing with special reference to the measurement of turbidity. J Immunol 1947; 57:211.Google Scholar
  44. 44.
    Hack CE, Ogilvie AC, Eisele B, et al. Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy. Prog Clin Biol Res 1994;388:335–357.PubMedGoogle Scholar
  45. 45.
    Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 1995;91:393–402.PubMedGoogle Scholar
  46. 46.
    Vesentini S, Benetti L, Bassi C, et al. Effects of choline-esterase inhibitor in experimental acute pancreatitis in rats. Int J Pancreatol 1993;13:217–220.PubMedGoogle Scholar
  47. 47.
    Cicardi M, Testoni P, Bergamaschini L, et al. Antiproteasic activity of C1 inhibitor. Therapeutic perspectives. Ann Ital Med Int 1994;9:180–182.PubMedGoogle Scholar
  48. 48.
    Larvin M, Chalmers AG, McMahon MJ. Dynamic contrast-enhanced CT: Precise identification and localisation of pancreatic necrosis complicating acute pancreatitis. Br Med J 1990;330:1425–1428.Google Scholar
  49. 49.
    McMahon MJ. Plasma markers of pancreatic necrosis. In: Bradley III EI (ed). Acute pancreatitis: Diagnosis and therapy. New York: Raven 1994;47–55.Google Scholar
  50. 50.
    Ueyama M, Maruyama I, Osame M, Sawada Y. Marked increase in plasma interleukin-6 in burn patients. J Lab Clin Med 1992;120:693–698.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • Rikard Berling
    • 1
    • 2
  • Kjell Ohlsson
    • 2
  1. 1.Department of AnaesthesiologyUniversity Hospital MASMalmöSweden
  2. 2.Department of Surgical PathophysiologyUniversity Hospital MASMalmöSweden

Personalised recommendations